Literature DB >> 22200495

Focal nonconvulsive seizures during detoxification for benzodiazepine abuse.

Anna Albiero1, Francesco Brigo, Marco Faccini, Rebecca Casari, Gianluca Quaglio, Monica Storti, Antonio Fiaschi, Luigi Giuseppe Bongiovanni, Fabio Lugoboni.   

Abstract

Chronic benzodiazepine (BDZ) abuse is currently treated with detoxification using a low-dose flumazenil infusion, a relatively recently developed and promising procedure. Given the possibility reported in the literature of the occurrence of generalized seizures during therapeutic BDZ detoxification, we usually administer preventive antiepileptic drug (AED) therapy. We describe two patients with no previous history of seizures or evidence of intracerebral lesions who, during detoxification for benzodiazepine abuse, developed repetitive focal nonconvulsive seizures instead of generalized seizures, even with appropriate doses of preventive AED therapy. There are no previous reported cases of focal nonconvulsive seizures occurring during this procedure or, more generally, during abrupt BDZ discontinuation. The cases we describe suggest that during detoxification for BDZ abuse, not only generalized, but also focal nonconvulsive seizures may occur. In this context, the focal seizures probably result from a diffuse decrease in the seizure threshold (caused by a generalized excitatory rebound), which may trigger focal seizures arising from cortical regions with higher intrinsic epileptogenicity. Detoxification for benzodiazepine abuse, even if performed with adequate-dosage AED treatment, may not be as safe a procedure as previously considered, because not only convulsive, but also nonconvulsive seizures may occur and go unnoticed. It is therefore strongly advisable to perform this detoxification under close medical supervision and to maintain a low threshold for EEG monitoring in the event of sudden onset of behavioral changes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22200495     DOI: 10.1016/j.yebeh.2011.11.005

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

1.  Exploring the dark side of the moon: the treatment of benzodiazepine tolerance.

Authors:  Fabio Lugoboni; Gianluca Quaglio
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 2.  Benzodiazepine dependence and its treatment with low dose flumazenil.

Authors:  Sean David Hood; Amanda Norman; Dana Adelle Hince; Jan Krzysztof Melichar; Gary Kenneth Hulse
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 3.  Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.

Authors:  Rainer Freynhagen; Miroslav Backonja; Stephan Schug; Gavin Lyndon; Bruce Parsons; Stephen Watt; Regina Behar
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

4.  Focal bilateral motor seizures precipitated by abrupt cessation of chronic lormetazepam abuse and amitriptyline overdose.

Authors:  Rosario Rossi; Francesca Di Stefano; Sara Lizzos; Gianluca Deiana
Journal:  Epilepsy Behav Rep       Date:  2020-07-31

5.  Addiction of High Dose of Benzodiazepine: Verona Detox Approach With Flumazenil.

Authors:  Rebecca Casari; Antonio Metastasio; Lorenzo Zamboni; Martino Biasioli; Simone Campagnari; Fabio Lugoboni
Journal:  Front Psychiatry       Date:  2022-03-31       Impact factor: 4.157

6.  Clonazepam as agonist substitution treatment for benzodiazepine dependence: a case report.

Authors:  Angelo Giovanni Icro Maremmani; Luca Rovai; Fabio Rugani; Silvia Bacciardi; Matteo Pacini; Liliana Dell'osso; Icro Maremmani
Journal:  Case Rep Psychiatry       Date:  2013-01-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.